Quality, comprehensiveness and excellence


Revised European Quality Standards for Cancer Networks will be piloted at OncoZON

April 29, 2022 

The OECI A&D Board has approved the revised version (5.3) of the European Quality Standards for Cancer Networks. This revision is based on the experiences of the 1st pilot of the Network standards at the Association Toulousaine d'Oncologie Publique (ATOP) in Toulouse in April 2021. 

The OncoZON (Oncology Network SouthEast Netherlands) Network, consisting of the Maastricht University Medical Centre (MUMC+), 8 other regional hospitals and a radiotherapy institute in Maastricht, has agreed to participate in the 2nd pilot for the OECI European Network Standards certification.


New standards in Manual 3.2 per March 2022

February 24, 2022 
The OECI standards focus on what is critical to cancer care and research. During the IsquaEEA re-accreditation process for our standards, we have reviewed the IEEA standards and found it necessary to add some standards, related to Infection control and Training and support for volunteers, which are essential for cancer care and were missing in Manual 3.1. All centres applying for the A&D Programme for March 2022 will be accredited according to Manual 3.2.

Please find below an overview of the new standards:
Standard 11: Quality Assurance

New chair A&D Board

January 12, 2022 

As of 1 January 2022 Simon Oberst has stepped down as Chair of the A&D Board and will be succeeded by dr. Jean-Benoît Burrion, Deputy Medical Director of Institut Jules Bordet in Brussels.

Simon has been appointed Director of Quality Improvement at OECI from 1 February 2022 and will be responsible for all aspects of Quality Improvement in Cancer Centres, including the A&D Programme and European projects. He will continue to serve on the A&D Board as a non-voting member. OECI wishes both Jean-Benoit and Simon every success in their new roles. 


Call for new auditors OECI A&D Programme

July 21, 2021 

Performing a peer review visit as an OECI auditor is a learning experience in your own professional life, in the fight against cancer in your own Centre, as well as a crucial part of ensuring quality improvement in an applicant Cancer Centre.

During a peer review visit you will have the opportunity to examine all aspects of the Cancer Centre, both the organisation at the management level and at the clinical and laboratory level for all disciplines, e.g. for nurses, physicians, researchers, pathologists, management etc.


100 CORE standards article

May 14, 2021 
In August 2020, the Accreditation and Designation Board of OECI published the results of two years revision work on the Quality Standards for our cancer centres in Europe. Part of this exercise was to select by consensus the Core Standards for quality care and research infrastructure which would be regarded as essential to apply across Europe, and which OECI will use as core requirements in every (re-)accreditation of a cancer centre, and require full evidence of compliance. .

European Cancer Network Standards evaluated in pilot visit

May 14, 2021 

Building upon our highly successful quality accreditation programme for Cancer Centres and Comprehensive Cancer Centres (now involving nearly 60 large centres, with our standards being certified by ISQua) the A&D programme has now developed (with the aid of multiple professional and patient organisations) a set of quality standards for cancer networks, which evaluate the effectiveness of each cancer network structure.  These European Cancer Network Standards are in draft form and are being evaluated in pilot visits.


Revisions Appendix III Manual 3.0 (Quantitative questionnaire)

April 15, 2021 Pharmacy with unit dedicated to Oncology (instead of Oncology Pharmacy) Definition accrual into prospective interventional trials:
Participants in cohort-based observational biomarker-driven studies are NOT included in the number forming the percentage for Designation. We do ask for the data of cohort-based observational studies (see question ), provided that they concern studies with a formal PI role from the centre, and approved by scientific and ethical review committees.


Revisions Appendix II Manual 3.0 (Qualitative questionnaire)

April 15, 2021 
When working on the template for the peer review report of Manual 3.0 as well as the IEEA accreditation of the OECI standards of Manual 3.0, we have noticed some revisions, which have not been taken over in the Manual 3.0, as this was published before the revisions were made. We herewith inform you of these minor changes:
  • Some standards have been upgraded to CORE standards: standard 12.5, 32.1, 40.1, 40.3, 40.9, 41.1, 41.3, 41.9, 46.2, 47.2, 50.6
  • One standard was downgraded from a CORE standard: standard 57.

Changes to the composition of the OECI A&D Board and Accreditation Committee

March 08, 2021 

We are happy to announce that Dr Jozsef Lovey, a present member of the Accreditation Committee and Medical Director of the National Institute of Oncology in Budapest, has agreed to chair the Committee, in succession to Prof Gunnar Saeter.  Gunnar has done an amazing job over the last 6 years, streamlining the committee’s work at a time of strong growth in the programme, and providing robust and detailed advice on accreditation decisions to the Accreditation & Designation Board.


OECI audits: from on-site to hybrid to 100% virtual

December 18, 2020 

The Covid-19 virus has a major impact on the way everyone works. This also applies to the work for the Accreditation and Designation programme of the OECI.

This spring, the audit for the Cancer Centre in Reggio Emilia was cancelled in a hurry after it became clear that the number of Covid-19 patients in the northern provinces of Italy was rapidly increasing at the end of February. The number of Covid-19 cases also increased rapidly in the rest of Europe.

1 2 3 4 5